Central Nervous System Biodistribution and Pharmacokinetics of Radiolabeled Tofersen in Rodents, Nonhuman Primates, and Humans

Brendon E. Cook, Donald G. McLaren, Jenna M. Sullivan, Georges El Fakhri, Daniel Yokell, Mason W. Freeman, Nicolas Currier, Michael Oestergaard, Howard Dobson, Jacob Hesterman, Nicolas Salem, Ivan Nestorov, Michael Monine, Laurent Martarello, Karleyton C. Evans, Stephanie Fradette, Toby A. Ferguson, Danielle Graham, Luca PassamontiJournal of Nuclear Medicine 2025 · DOI

TL;DR

This study successfully developed and validated a radiolabeled version of the ASO tofersen ([<sup>99m</sup>Tc]Tc-MAG3-tofersen) for non-invasive imaging of drug distribution in the central nervous system (CNS). The findings demonstrate broad uptake in the brain and spinal cord across rodents, nonhuman primates, and humans, providing crucial insights into ASO pharmacokinetics and supporting the development of future CNS-targeted therapies.

What Problem Does This Paper Address?

Antisense oligonucleotides (ASOs) are a promising class of therapeutics, but their distribution and behavior within the central nervous system (CNS), particularly in humans, remain poorly understood. This lack of detailed pharmacokinetic and biodistribution data hinders the optimization of ASO delivery for neurological diseases. Specifically, characterizing how ASOs reach target brain regions and how they are cleared is essential for designing more effective treatments. This paper addresses this gap by developing a method to visualize and quantify ASO distribution in vivo, bridging the divide between preclinical models and human studies.

Methods

The core innovation of this study is the development of a radiolabeled tracer, [<sup>99m</sup>Tc]Tc-MAG3-tofersen. Tofersen, an ASO approved for SOD1-ALS, was chemically modified by conjugating it to a MAG3 moiety. This moiety acts as a chelator, allowing it to bind the radioactive isotope technetium-99m (<sup>99m</sup>Tc). This radiolabeled compound was designed to serve as a proxy for the unlabeled therapeutic drug.

The researchers then employed Single-Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) imaging to track the distribution of this radiolabeled tracer. Preclinical studies were conducted in rats and nonhuman primates (NHPs) where the tracer was administered intrathecally (directly into the cerebrospinal fluid via lumbar puncture), mimicking the clinical route of administration. In parallel, a first-in-human imaging trial was performed with healthy volunteers, also receiving intrathecal administration of the radiolabeled tracer alongside a therapeutic dose of unlabeled tofersen. This multi-species approach allowed for comparison of ASO biodistribution and pharmacokinetics across different biological systems.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Bridging the Preclinical-Human Divide: The development of [<sup>99m</sup>Tc]Tc-MAG3-tofersen provides a crucial tool for directly comparing ASO behavior in animal models to humans, a significant step in translating preclinical findings.
  • Consistent Broad CNS Uptake: Across all species studied (rats, NHPs, and humans), the radiolabeled ASO showed widespread distribution throughout the spinal cord and brain after intrathecal administration. This supports the hypothesis that ASOs can access these critical areas.
  • Species-Specific Clearance Kinetics: While initial distribution patterns were similar, the clearance of the ASO from the CNS differed notably between humans and preclinical models. Humans showed increasing brain uptake in the initial hours, whereas rodents and NHPs exhibited declining concentrations. Similarly, spinal cord clearance plateaued earlier in animals compared to humans.
  • Peripheral Clearance: In all species, the primary routes of peripheral clearance for the ASO were identified as the liver and kidneys, which is a common pathway for many drug molecules.
  • Safety and Tolerability: The human trial demonstrated that co-administering the microdose of radiolabeled tofersen with a therapeutic dose of unlabeled tofersen was well-tolerated, with no serious adverse events reported. Human dosimetry estimates also fell within safe radiation dose limits.

Key Results

  • Radiochemical Purity: The synthesized [<sup>99m</sup>Tc]Tc-MAG3-tofersen tracer was prepared with greater than 99% radiochemical purity.
  • Proxy Validation: In rats, the biodistribution of [<sup>99m</sup>Tc]Tc-MAG3-tofersen was shown to be a reliable proxy for unlabeled tofersen.
  • Human Brain Uptake: In healthy volunteers, human brain uptake of the radiolabeled ASO increased during the first 4 hours post-injection.
  • Spinal Cord Clearance: Tracer clearance from the lumbar spine plateaued after 6 hours in rodents and NHPs but continued to decrease in humans over the 24-hour imaging period.
  • Dosimetry: Human dosimetry estimates were within safe radiation dose levels, with an estimated effective dose of 0.62 ± 0.112 mSv.

Limitations and Future Work

The authors acknowledge several limitations. Firstly, SPECT imaging, while valuable, has relatively low spatial resolution compared to techniques like PET. This limits the ability to assess ASO distribution in very small brain regions or differentiate between spinal cord and CSF with high precision. Secondly, the relatively short half-life of <sup>99m</sup>Tc (approximately 6 hours) constrained the imaging analysis to a 24-hour window, which is significantly shorter than the weeks-to-months half-life of ASOs themselves.

Future work could involve using longer-lived radioisotopes (e.g., <sup>89</sup>Zr) or alternative imaging modalities like PET to achieve higher resolution and longer observation periods. This would allow for a more comprehensive understanding of ASO pharmacokinetics over their full duration of action. The study also suggests that while rodent and NHP models are suitable for initial testing, the observed kinetic differences in humans highlight the importance of direct human imaging studies for accurate pharmacokinetic profiling. The developed radiolabeling approach is also presented as a versatile platform that can be applied to other ASOs, enabling broader drug development efforts.

Summary updated

Abstract

Antisense oligonucleotides (ASOs) are an important therapeutic modality across several therapeutic areas, offering currently available and potential future treatment options for patients. ASO pharmacokinetics, biodistribution, and regional brain uptake are not fully characterized, particularly in humans. Here, we report preclinical studies and the first-in-human imaging trial measuring the biodistribution of [<sup>99m</sup>Tc]Tc-MAG3-tofersen. The tracer was designed to be a proxy for tofersen (Qalsody; Biogen), an ASO approved for the treatment of amyotrophic lateral sclerosis in adults who have a variant in the <i>SOD1</i> gene (<i>SOD1</i>-ALS). <b>Methods:</b> Tofersen was conjugated to a MAG3 moiety, which chelates <sup>99m</sup>Tc to yield [<sup>99m</sup>Tc]Tc-MAG3-tofersen. [<sup>99m</sup>Tc]Tc-MAG3-tofersen and unlabeled tofersen were intrathecally injected in rats, nonhuman primates (NHPs), and healthy human volunteers (<i>n</i> = 3) via lumbar puncture, followed by SPECT/CT imaging. Tofersen was coadministered at a therapeutic dose. The tracer [<sup>99m</sup>Tc]Tc-MAG3-tofersen was prepared with greater than 99% purity. <b>Results:</b> Findings in rats demonstrated that [<sup>99m</sup>Tc]Tc-MAG3-tofersen was a proxy measure of unlabeled tofersen, and dosimetry was calculated from NHP imaging data. In a clinical study, unlabeled tofersen coadministered with a microdose of [<sup>99m</sup>Tc]Tc-MAG3-tofersen (≤129.5 MBq [3.5 mCi]) was well-tolerated. Human dosimetry estimates were within safe radiation dose levels. Imaging showed consistent distribution of radiolabeled ASO throughout the spinal cord and brain across species, with clearance patterns diverging in humans. Although rats and NHPs demonstrated declining brain concentrations over the study duration, human brain uptake increased during the first 4 h after injection. Additionally, tracer clearance from the spine in rodents and NHPs plateaued after 6 h but continued to decrease in humans. Radiolabeled ASO clearance from the lumbar spine was observed across all species, with peripheral clearance mediated primarily through the liver and kidneys. Broad uptake of the ASO in the brain and spinal cord is consistent with the clinical effects of tofersen observed in individuals with the <i>SOD1</i>-ALS variation. <b>Conclusion:</b> In preclinical and human SPECT/CT studies, [<sup>99m</sup>Tc]Tc-MAG3-tofersen mirrored unlabeled drug distribution, showing broad spinal cord and brain uptake, with some differences in kinetics among species.
BibTeX
@article{cook2025central,
  author = {Brendon E. Cook and Donald G. McLaren and Jenna M. Sullivan and Georges El Fakhri and Daniel Yokell and Mason W. Freeman and Nicolas Currier and Michael Oestergaard and Howard Dobson and Jacob Hesterman and Nicolas Salem and Ivan Nestorov and Michael Monine and Laurent Martarello and Karleyton C. Evans and Stephanie Fradette and Toby A. Ferguson and Danielle Graham and Luca Passamonti},
  title = {{Central Nervous System Biodistribution and Pharmacokinetics of Radiolabeled Tofersen in Rodents, Nonhuman Primates, and Humans}},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.125.270731},
}
Figure